secwatch.observer — SEC 8-K summary
======================================

Issuer:     NORTHWEST BIOTHERAPEUTICS INC (NWBO)
CIK:        0001072379
Form:       8-K
Filed at:   2026-07-17T23:48:55+00:00
Accession:  0001104659-26-084743
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review
--------------------------------------------------------------------------------

- MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.
- Company categorically refutes false rumors of MHRA rejection and notes possible stock manipulation.
- Rumors intensified after BNOS Annual Meeting where significant Phase 3 trial data were presented.
- Company continues constructive interactions with MHRA; MAA progressing towards first regulatory decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/0001104659-26-084743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072379/000110465926084743/tm2620800d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer